The global ophthalmic eye dropper market size is anticipated to reach USD 20.02 billion by 2030, expanding at a CAGR of 6.01% from 2024 to 2030 according to a new study by Grand View Research, Inc. The rising prevalence of eye disorders such as glaucoma, age-related macular degeneration, and eye syndrome among the aging population worldwide has surged the demand for efficient treatments delivered through eye droppers. Moreover, advancements in drug delivery technologies and the introduction of preservative-free eye drops have notably improved patient adherence to treatment regimens. For instance, preservative-free drops are considered safer and preferred by individuals with dry eyes, thus allowing more frequent use.
The rise in eye conditions such as cataracts, glaucoma, dry eye syndrome, and allergies has significantly bolstered the demand for ophthalmic eye drops. For instance, as reported by the National Glaucoma Research, over 3 million Americans live with glaucoma, out of which 2.7 million are affected by the prevalent open-angle glaucoma among those aged 40 and older. This surge in prevalence aligns with the aging global population, contributing to the increasing occurrence of these conditions. Consequently, there's a pressing necessity for effective treatments like eye drops to address these escalating eye health challenges.
The increased awareness about maintaining optimal eye health and regular eye check-ups has improved the demand for ophthalmic eye drops. This proactive approach helps treat ophthalmic issues quicker which allows eye care providers and eye drops manufacturing companies to assist. For instance, companies like Alcon and Bausch + Lomb have made special eye drops for different eye problems, thereby fueling the market growth.
Request a free sample copy or view report summary: Ophthalmic Eye Dropper Market Report
In 2023, the preserved multi-dose eye dropper type segment accounted for the largest revenue share due to the rising prevalence of ophthalmic diseases and eye infections, coupled with the increased demand for convenient and cost-effective eye drop solutions
Based on drug type, the prescription drugs segment has always accounted for the largest revenue share in 2023, due to the high prevalence of eye disorders requiring prescription-based treatments, driving the demand for specific medications delivered through eye droppers
Based on treatment type, the dry eye segment accounted for the largest revenue share in 2023, due to rising prevalence of dry eye syndrome globally, inspiring a higher demand for specialized treatments delivered through eye droppers catering to the eye condition
North America held the largest share of the market in 2023 due to technological advancements and increasing prevalence of eye disorders, coupled with a growing aging population in the region
Market players adopt several strategic initiatives to increase the product reach and improve availability in diverse geographic areas
Grand View Research has segmented the global ophthalmic eye dropper market based on type, drug type, treatment type, and region:
Ophthalmic Eye Dropper Type Outlook (Revenue, USD Million, 2018 - 2030)
Unidose eye droppers
Preserved multi-dose eye droppers
Preservative-free multi-dose eye droppers
Ophthalmic Eye Dropper Drug Type Outlook (Revenue, USD Million, 2018 - 2030)
Prescription drugs
OTC drugs
Ophthalmic Eye Dropper Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)
Dry Eye
Glaucoma
Allergies
Conjunctivitis
Others
Ophthalmic Eye Dropper Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Norway
Sweden
Denmark
Asia Pacific
China
Japan
India
Thailand
South Korea
Australia
Latin America
Mexico
Brazil
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Ophthalmic Eye Dropper Market
AptarGroup, Inc.
Silgan Dispensing Systems
Alcon
Pfizer
Bausch & Lomb Incorporated
Novartis AG
AbbVie Inc.
"The quality of research they have done for us has been excellent..."